UPDATE: Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder

Palatin Technologies (NYSE: PTN ) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual